Schizophrenia and folate pharmacogenetics: Review of the literature regarding folic acid and its pharmacogenetically regulated metabolism in relation to schizophrenia treatments | Zendy

Andrew R. Wechter | Zendy; Kristen N. Gardner | Zendy; Tyler Grove | Zendy; Vicki L. Ellingrod | Zendy

Open Access

Schizophrenia and folate pharmacogenetics: Review of the literature regarding folic acid and its pharmacogenetically regulated metabolism in relation to schizophrenia treatments

Author(s) -

Andrew R. Wechter,

Kristen N. Gardner,

Tyler Grove,

Vicki L. Ellingrod

Publication year - 2012

Publication title -

mental health clinician

Language(s) - English

Resource type - Journals

ISSN - 2168-9709

DOI - 10.9740/mhc.n99731

Subject(s) - methylenetetrahydrofolate reductase , schizophrenia (object oriented programming) , pharmacogenetics , folic acid , medicine , antipsychotic , reductase , pharmacology , enzyme , psychiatry , gene , bioinformatics , biochemistry , biology , allele , genotype

Folic acid and its metabolism and utilization has become of increasing importance within the field of schizophrenia. Methylenetetrahydrofolate reductase (MTHFR) is the enzyme responsible for the formation of methyltetrahydrofolate (5-methyl THF) from dietary folate. Multiple studies have demonstrated relationships between MTHFR gene variants and schizophrenia. This review discusses these studies, and their findings regarding the relationship between different variants of the MTHFR gene and risk of antipsychotic-related metabolic syndrome, and the relationship between the pharmacogenetics of folate and the negative/cognitive symptoms of schizophrenia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research